Cargando…

When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis

Thrombocytopenia can arise from various conditions, including myelodysplastic syndromes (MDS) and bone marrow failure (BMF) syndromes. Meticulous assessment of the peripheral blood smear, identification of accompanying clinical conditions, and characterization of the clinical course are important fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonadies, Nicolas, Rovó, Alicia, Porret, Naomi, Bacher, Ulrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958851/
https://www.ncbi.nlm.nih.gov/pubmed/33801484
http://dx.doi.org/10.3390/jcm10051026
_version_ 1783664873320742912
author Bonadies, Nicolas
Rovó, Alicia
Porret, Naomi
Bacher, Ulrike
author_facet Bonadies, Nicolas
Rovó, Alicia
Porret, Naomi
Bacher, Ulrike
author_sort Bonadies, Nicolas
collection PubMed
description Thrombocytopenia can arise from various conditions, including myelodysplastic syndromes (MDS) and bone marrow failure (BMF) syndromes. Meticulous assessment of the peripheral blood smear, identification of accompanying clinical conditions, and characterization of the clinical course are important for initial assessment of unexplained thrombocytopenia. Increased awareness is required to identify patients with suspected MDS or BMF, who are in need of further investigations by a step-wise approach. Bone marrow cytomorphology, histopathology, and cytogenetics are complemented by myeloid next-generation sequencing (NGS) panels. Such panels are helpful to distinguish reactive cytopenia from clonal conditions. MDS are caused by mutations in the hematopoietic stem/progenitor cells, characterized by cytopenia and dysplasia, and an inherent risk of leukemic progression. Aplastic anemia (AA), the most frequent acquired BMF, is immunologically driven and characterized by an empty bone marrow. Diagnosis remains challenging due to overlaps with other hematological disorders. Congenital BMF, certainly rare in adulthood, can present atypically with thrombocytopenia and can be misdiagnosed. Analyses for chromosome fragility, telomere length, and germline gene sequencing are needed. Interdisciplinary expert teams contribute to diagnosis, prognostication, and choice of therapy for patients with suspected MDS and BMF. With this review we aim to increase the awareness and provide practical approaches for diagnosis of these conditions in suspicious cases presenting with thrombocytopenia.
format Online
Article
Text
id pubmed-7958851
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79588512021-03-16 When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis Bonadies, Nicolas Rovó, Alicia Porret, Naomi Bacher, Ulrike J Clin Med Review Thrombocytopenia can arise from various conditions, including myelodysplastic syndromes (MDS) and bone marrow failure (BMF) syndromes. Meticulous assessment of the peripheral blood smear, identification of accompanying clinical conditions, and characterization of the clinical course are important for initial assessment of unexplained thrombocytopenia. Increased awareness is required to identify patients with suspected MDS or BMF, who are in need of further investigations by a step-wise approach. Bone marrow cytomorphology, histopathology, and cytogenetics are complemented by myeloid next-generation sequencing (NGS) panels. Such panels are helpful to distinguish reactive cytopenia from clonal conditions. MDS are caused by mutations in the hematopoietic stem/progenitor cells, characterized by cytopenia and dysplasia, and an inherent risk of leukemic progression. Aplastic anemia (AA), the most frequent acquired BMF, is immunologically driven and characterized by an empty bone marrow. Diagnosis remains challenging due to overlaps with other hematological disorders. Congenital BMF, certainly rare in adulthood, can present atypically with thrombocytopenia and can be misdiagnosed. Analyses for chromosome fragility, telomere length, and germline gene sequencing are needed. Interdisciplinary expert teams contribute to diagnosis, prognostication, and choice of therapy for patients with suspected MDS and BMF. With this review we aim to increase the awareness and provide practical approaches for diagnosis of these conditions in suspicious cases presenting with thrombocytopenia. MDPI 2021-03-02 /pmc/articles/PMC7958851/ /pubmed/33801484 http://dx.doi.org/10.3390/jcm10051026 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bonadies, Nicolas
Rovó, Alicia
Porret, Naomi
Bacher, Ulrike
When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis
title When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis
title_full When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis
title_fullStr When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis
title_full_unstemmed When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis
title_short When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis
title_sort when should we think of myelodysplasia or bone marrow failure in a thrombocytopenic patient? a practical approach to diagnosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958851/
https://www.ncbi.nlm.nih.gov/pubmed/33801484
http://dx.doi.org/10.3390/jcm10051026
work_keys_str_mv AT bonadiesnicolas whenshouldwethinkofmyelodysplasiaorbonemarrowfailureinathrombocytopenicpatientapracticalapproachtodiagnosis
AT rovoalicia whenshouldwethinkofmyelodysplasiaorbonemarrowfailureinathrombocytopenicpatientapracticalapproachtodiagnosis
AT porretnaomi whenshouldwethinkofmyelodysplasiaorbonemarrowfailureinathrombocytopenicpatientapracticalapproachtodiagnosis
AT bacherulrike whenshouldwethinkofmyelodysplasiaorbonemarrowfailureinathrombocytopenicpatientapracticalapproachtodiagnosis